Evaluation of Down syndrome screening strategies.
Women contemplating pregnancy today have many different Down syndrome screening protocols from which to choose. Sensitive and specific first and second trimester screening protocols are now widely available, and strategies that combine first and second trimester markers are moving from investigational use into the clinical arena. Modeling indicates that a high detection rate (85%) associated with a very low screen positive rate (1.3%) can be achieved with contingent screening, in which all women undergo first trimester screening and only a portion (25%) go on to second trimester screening.
Wenstrom
Katharine D
KD
Department of Obstetrics and Gynecology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA. kwenst@uab.edu
D000328:Adult; D000649:Amniocentesis; D006063:Chorionic Gonadotropin / Q000097:blood; D015193:Chorionic Villi Sampling; D004314:Down Syndrome / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging; D005260:Female; D005315:Fetal Diseases / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging; D005333:Fetus; D006801:Humans; D048208:Nuchal Translucency Measurement; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism; D012680:Sensitivity and Specificity; D016216:Ultrasonography, Prenatal / Q000379:methods; D000509:alpha-Fetoproteins / Q000378:metabolism
D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D011266:Pregnancy-Associated Plasma Protein-A